Suboxone is a prescription medication used to treat opioid dependence. It combines two active ingredients: buprenorphine, which eases withdrawal symptoms and cravings, and naloxone, which discourages misuse. The FDA approved it specifically as part of a broader treatment plan that includes counseling and psychosocial support.
How Suboxone Works
Buprenorphine, the primary ingredient, is a partial opioid agonist. That means it activates the same receptors in the brain that opioids like heroin or prescription painkillers do, but it produces much weaker effects. It takes the edge off withdrawal and reduces cravings without delivering the intense high of a full opioid. This partial activation also creates a “ceiling effect,” where taking more beyond a certain point doesn’t increase the effects, which makes overdose less likely compared to full opioids.
Naloxone, the second ingredient, is included to discourage misuse. If someone dissolves and injects the film instead of taking it as directed, the naloxone blocks opioid receptors and can trigger immediate withdrawal symptoms. When Suboxone is taken under the tongue as prescribed, naloxone is poorly absorbed and has little effect.
Primary Use: Opioid Use Disorder
Suboxone’s core purpose is treating opioid dependence, whether that dependence developed from prescription painkillers, heroin, or synthetic opioids like fentanyl. It works in two phases: induction (getting started) and maintenance (staying stable long-term).
During induction, timing matters enormously. The first dose should only be taken once you’re already in moderate withdrawal, typically at least 12 hours after your last use of a short-acting opioid or 24 hours after a long-acting one. If you take it too soon, while a full opioid is still active on your receptors, buprenorphine can displace that opioid and trigger what’s called precipitated withdrawal. This is a rapid, intense worsening of withdrawal symptoms caused by buprenorphine’s high affinity for opioid receptors knocking off the full agonist before it has naturally cleared. Providers use a standardized scoring system to confirm you’re in sufficient withdrawal before giving the first dose.
During maintenance, most patients stabilize on a daily dose placed under the tongue. The FDA’s recommended target is 16 mg per day of the buprenorphine component, though some patients do better at higher doses. A large study reported by the National Institute on Drug Abuse found that even at the recommended 16 mg dose, 59% of patients discontinued treatment within 180 days. Patients prescribed 24 mg daily were 20% less likely to drop out over that same period, suggesting that adequate dosing plays a significant role in whether people stay in treatment.
How It Compares to Methadone
Both Suboxone and methadone treat opioid dependence, but they differ in important ways. Methadone is a full opioid agonist, meaning it carries a higher risk of overdose, especially early on. A study comparing the two found that during the first four weeks of treatment, the risk of drug-related overdose death was nearly five times higher for patients starting methadone than for those starting buprenorphine. After that initial period, the mortality risk between the two leveled out.
Methadone also requires daily visits to a specialized clinic for dosing, at least initially. Suboxone can be prescribed in a regular doctor’s office and taken at home. Since 2023, the old “X-waiver” requirement that limited which doctors could prescribe buprenorphine has been eliminated. Any practitioner with a standard DEA registration that includes Schedule III authority can now prescribe it, with no cap on the number of patients they treat. This change significantly expanded access.
Off-Label Use for Chronic Pain
Buprenorphine is sometimes prescribed for chronic pain, though this use is not as well supported by evidence as its role in treating opioid dependence. The VA/DoD clinical guidelines generally recommend against long-term opioid therapy for chronic pain but note that when opioids must be considered, buprenorphine may be preferable to other options because of its lower overdose risk and ceiling effect.
The evidence here is mixed. One small study of 35 patients found average pain scores dropped from 7.2 to 3.5 after switching to buprenorphine from other long-acting opioids. A systematic review of 25 trials covering five different buprenorphine formulations found clinically significant pain relief in 14 of them. But the overall quality of evidence remains low, with most studies being observational rather than randomized trials. For patients who have both chronic pain and opioid dependence, buprenorphine can address both problems simultaneously, which is where its strongest practical advantage lies.
Patients using buprenorphine for pain typically stabilize at lower doses than those treating opioid dependence. Because of the drug’s long half-life, it takes about five days to reach steady levels in the body, so dose adjustments happen gradually.
Common Side Effects
Suboxone is generally well tolerated, especially compared to full opioid agonists. The most frequently reported side effects include headache, nausea, constipation, insomnia, and sweating. In long-term studies, these tend to occur at low rates. One study of over 240 patients on buprenorphine found skin reactions in about 2.4%, itching in 1.2%, headache in 1.2%, nausea in under 1%, and constipation in under 0.5%.
Some people experience a mild opioid effect when they first start, including drowsiness or slight euphoria, but these effects are weaker than what full opioids produce and typically diminish as the body adjusts. The bigger concern for most patients is not side effects but the adjustment period of finding the right dose, one that controls cravings and withdrawal without excessive sedation.
What Treatment Looks Like
Suboxone comes as a film placed under the tongue, where it dissolves over several minutes. Treatment is not meant to be medication alone. The FDA label specifies it should be part of a complete plan that includes counseling and psychosocial support, whether that’s individual therapy, group programs, or recovery support services.
How long treatment lasts varies widely. Some people stay on Suboxone for months, others for years, and current clinical thinking generally favors longer treatment durations because the risk of relapse and overdose death rises significantly after stopping. For people dependent on long-acting opioids like methadone, the induction process requires extra caution, and providers may use buprenorphine alone (without naloxone) during the initial transition to reduce the risk of precipitated withdrawal.
The elimination of prescribing barriers in 2023 means more primary care doctors, nurse practitioners, and physician assistants can offer this treatment. New DEA registrants are required to complete at least eight hours of training on substance use disorders, or hold board certification in addiction medicine, ensuring a baseline level of competency even as access expands.